Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.34-0.53 (-4.47%)
As of 02:56PM EST. Market open.
Sign in to post a message.
  • S
    Sleujef
    If we were plunging 7 percent on heavy volume and if this supply had consistency and was generating significant downward results, I would be concerned. Down 7 percent on 2.7M means supply is lightweight and there currently is little demand. That could change in a split second and in the blink of an eye on heavy volume, we could be up 25 percent. If you haven't noticed, this stock has elasticity. My current predisposition here is short BCRX, as in I'm short the number of shares that I need to be satisfied. You cannot own enough of this security. Let these words be marked indelibly in your minds.
  • P
    Paul
    A critical detail of redeem 2 study on clinical trials.gov shows that after 12 weeks blinded placebo versus 9930, patients are unblinded and rolled over to All having the drug. This likely means that after 12 weeks of study we will have a data point of reporting and the potential for a surprise if efficacy is exceptional. Then there might be a push for more rapid authorization of the drug on ethical considerations. The recent huge cash reserve seems designed to carry The company through Studies and full marketing, and makes buy out less likely. And actually less desirable from my perspective. Looking at where we were a year ago leading into December 3 authorization for HAE, and CFO buying shares several months before that , history may repeat itself over the next 1 to 2 years! Very long and strong, this stock is a Goldmine for those who can wait
  • S
    SANTA CLAUS
    Why does this stock have such an uphill battle .. Compared to stocks that make no money smh
  • J
    Jamie
    Anybody who’s been watching the way BCRX trades in the last year knows that the stock price inextricably goes down on good news. More importantly, the stock will then start to rise steadily so I expect a nice finish to close out the year.
  • J
    John
    WE will be on cruise control for most of this year as REDEEM trial starts enrollment and readout won't be at least a year. Orladeyo's revenue is as expected and on target per senior management projections. The only wild card is how fast management burn thru cash. If they conserve cash and BCRX becomes profitable with Orladeyo's revenue, expect a bump up. If cash burn is severe and BCRX remains unprofitable, look for a drop. Any wild imagination speculations is fun to read but adds no value especially from annoyingmouserex who posts every few hours.
  • a
    anonymousrex
    John---You have no clue how biotech/pharma stocks work. The key factor is not the company getting into the black quickly---it is the amount of growth and the rate of growth in Rx's written, filled, refilled, and the amount of patients that have switched from other treatments to Orladeyo. do you understand the concept of compounded revenue or even recurring revenue? This is how pharma stocks grow. At this stage marketing and adoption by physicians and patients is MUCH more important than revenue vs. spending. Bio/pharma companies are FORCED to increase spending in the first year or 2 after approval to establish their drug in the marketplace. It is FUNDAMENTAL to the long-term growth of the company. Only an absolute blockhead would think that a company with a new drug on the market would HAVE to show a profit 4 quarters after approval. Show me significant growth, adoption, taking market share from Takhzyro-----and APPROPRIATE spending----and the stock will be rewarded.
  • a
    anonymousrex
    Bob---I do not believe in socialism. I am a capitalist, which is why I think parts of the American system are wonderful. But, there are definitely some changes I think should be made. I am not rich by any means, and when I have to pay my taxes, it hurts a bit, but I understand that in order to maintain and fund the American experience, and "pay my fair dues" to live in this great country it is necessary. I have no problem with the wealthiest Americans paying a few more percentage points in taxes if it will give my children and grandchildren a better life----and I don't mean handouts. I don't like the idea of "paid" community college. But I do like the idea of having better internet, cleaner water, better roads and airports, better healthcare, SOME green energy, less worry about the climate, and many other programs. Those multimillionaires and billionaires will not see their lives change one bit if they have to pay an extra 2-3% in REAL taxes, whereas the average JOE or even an upper middle class JOE with a few children would feel the burden of even a few hundred or a few thousand dollars more in taxes to fund those programs. That's all. And I expect the Medicare and Social Security benefits that I have been paying for my entire life, and am now nearing the time that I will need them to be there to be funded-----as promised. You can't just criticize and complain without proposing any alternatives. That was the problem with Obamacare. It was always "repeal and replace", except there was no replacement plan and no real attempt to come up with one. Now---let's get the roads and bridges fixed, get rid of COVID, and move FORWARD-----not backward.
  • P
    PJ
    Odd...stock is up, Jan $15 calls lost premium and are down about .10 to .15. With news of the trials of BCX9930 starting, this stock should be at $15 today. Talk about manipulation!
  • A
    Adam
    Long BCRX for over a year , mid 5 dollar range , held through the ups and downs, will not shake me lose , waiting for the tipping point to go on a bull run that we are all looking forward to 👍
  • M
    Michael
    BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
  • G
    Geoffrey
    Where is this red coming from, oh wait, it's what I've been saying for half a year now 11-12 ;-) I hope for your sakes that I will hold 11 by the end of the year or 2022 could even be worse then I expect
  • S
    SANTA CLAUS
    Man did anyone checkout Lisa's knockers yesterday whoo
  • a
    anonymousrex
    So now the NASDAQ is down over 900 points in the last 10 days. Sold 2000 shares today, but added 4000 more.
  • C
    Crash
    JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Biocryst Pharmaceuticals on Monday, setting a price target of $21, which is approximately 68.27% above the present share price of $12.48.
  • a
    anonymousrex
    Looking for a nice move higher tomorrow----and STAYING higher this time. While a loss of 2 cents is far from impressive, it did come on a day when the NASDAQ was down over 300 points. The $400,000+ open market purchase of stock by the CFO is the vote of confidence that every biotech hopes for. And the buy came AFTER the announcement of the $350 million cash infusion. No worries about dilution, no worries about short-term cash burn to stimulate Orladeyo sales, No worries about having enough cash to get through the pivotal 9930 trial. And if you are worried about the stock price---don't be. I have a feeling it is artificially being kept down for now, but elevator is getting ready to begin rising again. Too much good news coming all at once. Opportunity is knocking. Are you going to answer the door? This is a double within 12 months.
  • G
    George
    The financial news about Warren Buffet recently increased investment in Royalty Pharma led me to look into what that company is. They have assembled a portfolio of royalties which entitles them to payments based directly on the top-line sales of many of the industry’s leading therapies, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. Interesting is per their corporate presentation, they also acquired the royalties of Orladeyo and BCX9930 in 2020.

    They have made > 265 initial reviews of royalty candidates in 2020 but only 8 successful transactions of $2.4B, maintaining strong financial discipline of ~3% of initial reviews resulted in an executed transaction. That is a strong vote of confidence on Orladeyo and BCX9930 to me.
  • H
    Horkos
    Jmp reiterated their buy rating and price target of $21 as of today.
  • P
    PJ
    This is important and positive on so many levels...additional cash to develop BCX9930, as well as other potential blockbusters, additional funding to further promote Orladeyo; future partnership/buyout opportunities, but most of all--a strong vote of CONFIDENCE in what BCRX is doing. No company drops $350M unless they are extremely bullish on what BCRX is doing. This stock should actually be at $15 today.
  • a
    anonymousrex
    Just added another 1000 at $11.99 PM. .59 lower than CFO. 9930 finally enrolling with the first data readout likely after 12 weeks of data accumulated. 2022 is going to be a historic year for BCRX-----and the stock should easily reach a new high. Looking for mid $20's following first REDEEM data readout.
  • M
    Mitchell
    No matter what we do with the market in the doldrums there is only 3 things that will make this stock rise to the level that it should be.
    1) Additional countries approving.
    2) Proof of lower cash burn.
    3)Higher sales than anticipated